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Objectives: Polymyxin B is being increasingly utilized as a last resort against resistant Gram-negative bacteria. We
examined the pharmacodynamics of novel dosing strategies for polymyxin B combinations to maximize efficacy
and minimize the emergence of resistance and drug exposure against Acinetobacter baumannii.
Methods: The pharmacodynamics of polymyxin B together with doripenem were evaluated in time–kill experi-
ments over 48 h against 108 cfu/mL of two polymyxin-heteroresistant A. baumannii isolates (ATCC 19606 and
N16870). Pharmacokinetic/pharmacodynamic relationships were mathematically modelled using S-ADAPT.
A hollow-fibre infection model (HFIM) was also used to simulate clinically relevant polymyxin B dosing strategies
(traditional, augmented ‘front-loaded’ and ‘burst’ regimens), together with doripenem, against an initial inocu-
lum of 109 cfu/mL of ATCC 19606.
Results: In static time–kill studies, polymyxin B concentrations.4 mg/L in combinationwith doripenem25 mg/L
resulted in rapid bactericidal activity against both strains with undetectable bacterial counts by 24 h. The math-
ematical model described the rapid, concentration-dependent killing as subpopulation andmechanistic synergy.
In the HFIM, the traditional polymyxin B combination regimen was synergistic, with a .7.5 log10 reduction by
48 h. The polymyxin B ‘front-loaded’ combination resulted in more rapid and extensive initial killing (.8 log10)
within 24 h, which was sustained over 10 days. With only 25% of the cumulative drug exposure, the polymyxin
B ‘burst’ combination demonstrated antibacterial activity similar to traditional and ‘front-loaded’ combination
strategies. The polymyxin B ‘front-loaded’ and ‘burst’ combination regimens suppressed the emergence of
resistance.
Conclusions: Early aggressive dosing regimens for polymyxin combinations demonstrate promise for treatment
of heteroresistant A. baumannii infections.
Introduction
The emergence of antimicrobial resistance is a major threat to
human health and is jeopardizing our ability to treat infections.1
Gram-negative resistance is at the top of the infectious diseases
research agenda,2 as new therapeutic options are urgently
needed. The CDC has highlighted Acinetobacter baumannii, a
Gram-negative ‘superbug’, as a serious threat to human health.3
Gram-negative pathogens account for 70% of the infections
among intensive care unit patients and there has been an alarm-
ing increase in the incidence of nosocomial infections caused by
A. baumannii.4
A. baumannii is an extremely difficult pathogen to treat as
it has an ability to adapt through multiple mechanisms of re-
sistance in the face of antibiotic therapy. Clinicians have already
been confronted with the reality of infections caused by
A. baumannii strains that are resistant to all clinically available
agents except polymyxins (polymyxin B and colistin) and tigecyc-
line.5,6 Together with the first report of plasmid-mediated poly-
myxin resistance in E. coli that could be transferred to other
Gram-negative strains,7 the reports send a very strong warning.
Colistin is administered as an inactive prodrug, colistin methane-
sulfonate (CMS), and requires conversion in vivo into the active
form of colistin, a process that occurs slowly and incompletely
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in humans.8 Polymyxin B does not suffer from these limitations as
it is administered as the active antibiotic. The pharmacokinetic
(PK) and pharmacodynamic (PD) knowledge necessary to opti-
mize dosing for polymyxin B is limited,9,10 and suboptimal dosing
at currently recommended doses may have contributed to
increased resistance in Gram-negative pathogens.10,11 Dose
escalation of daily doses of polymyxin B is impractical as nephro-
toxicity is amajor dose-limiting adverse effect that occurs in up to
60% of patients even with currently recommended dosage regi-
mens as administered.12 –14 Polymyxin B combination therapy
has been shown to be more effective against MDR A. baumannii
strains as compared with monotherapy with polymyxin B.15,16
Previous in vitro studies have shown that polymyxin combinations
with a carbapenem are highly bactericidal against A. baumannii17
although the rapid bactericidal activity of this combination is fol-
lowed by regrowth with the emergence of resistant subpopula-
tions.18 Therefore, this underscores the need to develop novel
strategies to combat A. baumannii focused on polymyxin combi-
nations tomaximize bactericidal activity, minimize resistance and
decrease drug exposure.
In an attempt to define optimal dosing strategies for poly-
myxin B combinations with doripenem, we first examined via sta-
tic time–kill studies the concentration– response relationship
across a wide range of polymyxin B and doripenem concentra-
tions alone and in combination against A. baumannii. Next, we
employed mechanism-based mathematical models to guide
the design of new polymyxin B combination regimens. Finally,
we simulated traditional and novel polymyxin B combination regi-
mens in the hollow-fibre infection model (HFIM) and profiled the
dynamics of subpopulations over 10 days.
Materials and methods
Antibiotics, medium and bacterial isolates
Analytical grade polymyxin B sulphate was purchased from Sigma-Aldrich
(St Louis, MO, USA) and doripenemwas provided by Shionogi Inc. (Florham
Park, NJ, USA). Fresh stock solutions of polymyxin B and doripenem were
prepared immediately prior to each experiment and filter sterilized using a
0.22 mm Millex GP filter (Millipore, Bedford, MA, USA). Cation-adjusted
Mueller–Hinton broth (CAMHB) (Difco, Detroit, MI, USA) supplemented
with calcium (25 mg/L) and magnesium (12.5 mg/L) was used as the
growth medium for all time–kill and HFIM experiments.
MIC values were determined in quadruplicate according to CLSI guide-
lines.19 A. baumannii ATCC 19606 (polymyxin B MIC 0.5 mg/L; doripenem
MIC 2 mg/L) and a clinical isolate N16870 (polymyxin BMIC 0.5 mg/L; dori-
penem MIC 16 mg/L) were studied. Both isolates were polymyxin hetero-
resistant, demonstrating the presence of subpopulations on agar plates
containing .2 mg/L polymyxin B.20
Time–kill experiments
Static time–kill experiments were performed as previously described21
against a starting inoculum (108 cfu/mL) over 48 h to characterize the
concentration–effect relationship of polymyxin B and doripenem. In
brief, prior to each experiment, bacterial isolates were subcultured on
Mueller–Hinton agar and incubated overnight at 378C. Bacteria from the
overnight growth were added to CAMHB to produce a bacterial suspension
thatwas subsequently diluted to provide the starting inoculummentioned
above. Serial samples were collected at 0, 1, 2, 4, 6, 8, 24, 28, 32 and 48 h
for the determination of bacterial counts. After appropriate dilutions with
saline, samples of bacterial cell suspension (50 mL) were spirally plated on
Mueller–Hinton agar plates using a Whitley automatic spiral plater (WASP;
Don Whitley Scientific, Shipley West Yorkshire, UK). Colonies were counted
by a ProtoCOL automated colony counter (Synbiosis, Cambridge, UK) after
an incubation period of 24 h at 378C. The lower limit of counting was
20 cfu/mL. Time–kill experimentswere conducted at polymyxin B concentra-
tions of 0.5, 1, 2, 4, 8, 16, 32 and 64 mg/L, and a doripenem concentration of
25 mg/L, alone and in combination.
HFIM
The HFIM was used to evaluate the effect of selected polymyxin B and dori-
penemmonotherapyand combination regimens on bacterial burden and sup-
pression of resistance against A. baumannii ATCC 19606 over 240 h, as
previously described.22 Cellulosic hollow-fibre cartridges (C3008; Fiber Cell
System, Inc., Fredrick, MD, USA) were utilized in all experiments. Twenty-three
samples (0.5 mL) were serially collected over 240 h to determine bacterial
counts for each experiment. Samples were quantified for the total population
by depositing appropriately diluted bacterial samples on CAMHA plates, as pre-
viously described.23 Aliquots of the diluted sample were plated on CAMHA
plates containing 0.5, 1, 2, 3, 4, 6, 8 or 10 mg/L polymyxin B for in-depth ana-
lysis of the time-course of resistant subpopulations at pre-dose at 24, 48, 72,
96, 144, 192 and 240 h, as previously described.20
HFIM experiments consisted of clinically achievablemonotherapy and
combination therapy regimens, which were informed by mechanism-
based population modelling of the static time–kill experiments. The
rationale for dosing polymyxin B as a continuous infusion was based
on the flat PK profile seen in critically ill patients receiving polymyxin
B. Patients in this study received polymyxin B doses ranging from 0.45
to 3.38 mg/kg/day every 12 h. Based on this previous study, the unscaled
population estimate of the half-life was 11.9 h and fAUCs ranged from
6.2 to 53.5 mg.h/L with a median of 26.5 mg.h/L, average of
29.4 mg.h/L and standard deviation of 10.4 mg.h/L.24 The experimental
design consisted of a no treatment control arm and eight monotherapy
and combination regimens, as follows:
(a) Polymyxin B traditional monotherapy: free steady-state concentration
(fCss) of 2 mg/L administered as a continuous infusion, based on the
PK in critically ill patients.24
(b) Polymyxin B traditional monotherapy: as above but with a fCss of
5 mg/L administered as a continuous infusion.
(c) Doripenem monotherapy: fCmax of 25 mg/L every 8 h based on PK in
critically ill patients.25
(d) Combination of polymyxin B traditional (fCss of 2 mg/L continuous
infusion) and doripenem (fCmax of 25 mg/L every 8 h).
(e) Combination of polymyxin B ‘front-loaded’ (fCss of 5 mg/L continuous
infusion for 24 h followed by fCss of 2 mg/L thereafter) and doripenem
(fCmax of 25 mg/L every 8 h).
(f) Combination of polymyxin B ‘burst 2’ (fCss of 2 mg/L continuous infu-
sion for 24 h followed by no polymyxin B thereafter) and doripenem
(fCmax of 25 mg/L every 8 h).
(g) Combination of polymyxin B ‘burst 5’ (fCss of 5 mg/L continuous infu-
sion for 24 h followed by no polymyxin B thereafter) and doripenem
(fCmax of 25 mg/L every 8 h).
(h) Combination of doripenem ‘burst’ (fCmax of 25 mg/L every 8 h×3
doses followed by no doripenem thereafter) and polymyxin B trad-
itional regimen (fCss of 2 mg/L continuous infusion).
Polymyxin B concentrations were quantified by analysing polymyxin B1
and B2 using a validated high-performance LC-MS/MS approach as
previously described by Cheah et al.26 Analysis of independently pre-
pared quality control samples indicated good reproducibility (coeffi-
cients of variation ≤8.39%) and accuracy (observed concentrations
were within ≤10.0% of target concentrations). The limit of quantifica-
tion was 0.1 mg/L.
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Population mathematical modelling of static
time–kill data
Mechanism-based population PD modelling was performed to estimate
the exposure–response relationship for time–kill studies for both bacterial
isolates to propose front-loaded and other novel regimens for evaluation
in the HFIM. Models with differing susceptibilities to polymyxin B and dori-
penem were considered. The final number of pre-existing subpopulations
was based on the objective function, plausibility of parameter estimates,
standard diagnostic plots and visual predictive checks. The total bacterial
populationwasmodelled as the sumof these pre-existing subpopulations.
The final model consisted of four subpopulations for ATCC 19606 and
N16870 (Figure S1, available as Supplementary data at JAC Online).
Bacterial replication was modelled using the life-cycle growth replication
model,21 in which each subpopulation was described by two states: a
vegetative state and a replicating state. The two states had the same sus-
ceptibility but differed in their growth phase. The action of polymyxin Bwas
described using a target site-binding model, and bacterial killing by poly-
myxin B wasmodelled as a second-order process. The killing effect of dori-
penem was described by a first-order saturable process.
Modelling the combinatorial PD of polymyxin B and
doripenem in the HFIM
The interaction between polymyxin B and doripenem was modelled by
considering two different synergistic interactions for the combination.
Polymyxin B and doripenem are not subject to the same resistance
mechanisms.27,28 Hence, the time-course of polymyxin B and doripenem
interactions wasmodelled as ‘subpopulation synergy’, in which polymyxin
B killed the doripenem-resistant subpopulations and vice versa. The
second synergistic interaction was ‘mechanistic synergy’, in which the kill-
ing activity of doripenemwas enhanced by polymyxin B and vice versa. The
final model included both proposed synergistic interactions of subpopula-
tion and mechanistic synergy (see the Supplementary data available at
JAC Online, including Figure S1 and the differential equations).
Model estimation
Candidate models describing the time-course of combination drug effects
on bacteria were simultaneously fitted to all viable total population count
profiles of the two isolates studied in time–kill experiments. Estimation
was performed using parallelized S-ADAPT software (version 1.57) facili-
tated by SADAPT-TRAN using the importance sampling Monte Carlo para-
metric expectation maximization method (pmethod¼4).29 An additive
residual error model on a log10 scale was used for bacterial counts
≥100 cfu/mL. To account for high sampling error at low concentrations,
an error model containing both proportional and Poisson distributions
was used for the bacteria.21
Results
The concentration–response profiles for polymyxin B alone and in
combination with doripenem against two A. baumannii isolates
with a starting inoculum of 108 cfu/mL based on static time–kill
studies are shown in Figure 1. The profiles with polymyxin B
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Figure 1. Observed and fitted viable counts for the time–kill experiments formono and combination therapies with polymyxin B and doripenemagainst
ATCC 19606 (a, c) and N16870 (b, d). PMB, polymyxin B; DOR, doripenem. This figure appears in colour in the online version of JACand in black andwhite in
the print version of JAC.
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concentrations of 0.5, 1.0 and 2.0 mg/L against both isolates
(Figure 1a and b) were no different from the growth control. High
polymyxin B concentrations of 16, 32 and 64 mg/L resulted in
early bactericidal activity by 8 h. However, extensive regrowth
was observed for all polymyxin B concentrations except at the high-
est concentration of 64 mg/L. Doripenem monotherapy displayed
minimal activity against both isolates with an inoculum of
108 cfu/mL (Figure 1c and d). Interestingly, the combination of
polymyxin B (across the concentration range 2–8 mg/L) and dori-
penem (25 mg/L) was markedly synergistic against both isolates.
Against a high bacterial density of ATCC 19606 (Figure 1c) and
N16870 (Figure 1d) polymyxin B≥2 mg/L in combinationwith dori-
penem demonstrated rapid bactericidal activity, while polymyxin B
≥4 mg/L in combination with doripenem resulted in undetectable
bacterial counts by 28 h.
The mathematical model described the rapid, concentration-
dependent killing of polymyxin B based on known mechanisms of
actionof polymyxin B anddoripenem. Themodel described the time-
courseof bacterial killing and regrowthwell (Figure 1). Populationpre-
dictions were reasonably precise and unbiased (Figure 2). Themodel
diagnostics generated based on observed viable counts versus indi-
vidual (population) fitted shown in Figure 2(a–d) indicates that the
individual fits for N16870 (R2¼0.949) were more precise as com-
pared with ATCC 19606 (R2¼0.938). On the other hand, the popula-
tion fits for ATCC 19606 (R2¼0.856) were better as compared with
those for N16870 (R2¼0.459). Based on the estimated EC50,
55.7% and 70.8% of the binding sites for Mg2+ and Ca2+
(Table S1) are required to be unoccupied by Mg2+ or Ca2+ to achieve
an effective polymyxin B concentration that is 50% of its concentra-
tion in broth for ATCC 19606 andN16870, respectively. Models with a
total of four subpopulations with differing susceptibilities to poly-
myxin B and doripenemwere adequate to describe the antibacterial
activity of polymyxin B and doripenem.
Based on the modelling of the time–kill data, polymyxin B
achieved 7.4-fold greater killing against the susceptible populations
of N16870 as compared with ATCC 19606, and killing of the
polymyxin-resistant subpopulations was much slower for both
strains (Table S1). In the model for doripenem monotherapy, the
maximumkilling rate constant (KmaxSS) of the doripenem-susceptible
subpopulationwas 1.19 h21 for ATCC 19606 and1.73 h21 for N16870.
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Figure 2. Observed versus individual fitted (population fitted) for ATCC 19606 (a, b) and N16870 (c, d).
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The killing of the doripenem-resistant subpopulation by doripenem
was estimated to be very slow. The combination was modelled as
polymyxin B effectively killing the doripenem-resistant subpopulations
and doripenem killing the polymyxin B intermediate and resistant sub-
populations with proposed synergistic interactions between subpopu-
lations and mechanisms (Figure S1).
In theHFIM, polymyxinB traditionalmonotherapy (fCss of 2 mg/L
continuous infusion) was bacteriostatic against A. baumannii strain
ATCC 19606, with,1 log10 cfu/mL killing over 240 h comparedwith
the growth control (Figure 3 and Figure 4). Emergence of resistance
by 24 h in real-time population analysis profiles confirmed the
emergence of resistance secondary to monotherapy with poly-
myxin B, with subpopulations growing on agar plates containing
0–10 mg/L polymyxin B (Figure 4 and Figure 5). Increasing the
exposure to polymyxin B in the HFIM with a polymyxin B traditional
monotherapy regimen (fCss of 5 mg/L continuous infusion) resulted
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Figure 3. An HFIM was utilized to simulate various mono and combination
regimens against a high inoculum of 109 cfu/mL of A. baumannii
ATCC 19606. PMB, polymyxin B; DOR, doripenem. The total bacterial
counts for the following regimens simulated: Control, growth control
with no antibiotic; DOR (25 mg/L q8h) monotherapy, DOR traditional
monotherapy (fCmax of 25 mg/L every 8 h); PMB (2 mg/L CI) monotherapy,
PMB traditional monotherapy (fCss of 2 mg/L administered as a continuous
infusion); PMB (5 mg/L CI) monotherapy, fCss of 5 mg/L administered as a
continuous infusion; PMB (2 mg/L CI)+DOR Burst (25 mg/L q8h for 24 h),
combination of PMB traditional (fCss of 2 mg/L continuous infusion) and
DOR ‘burst’ (fCmax of 25 mg/L every 8 h×3 doses followed by no DOR
thereafter); PMB (2 mg/L CI)+DOR (25 mg/L q8h), combination of PMB
traditional (fCss of 2 mg/L continuous infusion) and DOR (fCmax of 25 mg/L
every 8 h); PMB Burst (2 mg/L CI on day 1)+DOR (25 mg/L q8h),
combination of PMB ‘burst’ (fCss of 5 mg/L continuous infusion for 24 h
followed by no PMB thereafter) and DOR (fCmax of 25 mg/L every 8 h);
PMB Burst (5 mg/L CI on day 1)+DOR (25 mg/L q8h), combination of PMB
‘burst’ (fCss of 2 mg/L continuous infusion for 24 h followed by no PMB
thereafter) and DOR (fCmax of 25 mg/L every 8 h); PMB Front-Loading
(5 mg/L CI on day 1 then 2 mg/L CI thereafter)+DOR (25 mg/L q8h),
combination of PMB ‘front-loading’ (fCss of 5 mg/L continuous infusion for
24 h followed by fCss of 2 mg/L thereafter) and DOR (fCmax of 25 mg/L
every 8 h). This figure appears in colour in the online version of JAC and in
black and white in the print version of JAC.
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Figure 4. Population analysis profiles at 240 h profiling the emergence of
resistant subpopulations grown on polymyxin B-containing agar for the
regimens shown in Figure 3. PMB, polymyxin B; DOR, doripenem. Control,
bacterial subpopulations present at time 0 h (without any treatment);
DOR (25 mg/L q8h) monotherapy, DOR traditional monotherapy (fCmax of
25 mg/L every 8 h); PMB (2 mg/L CI) monotherapy, PMB traditional
monotherapy (fCss of 2 mg/L administered as a continuous infusion);
PMB (5 mg/L CI) monotherapy, fCss of 5 mg/L administered as a
continuous infusion; PMB (2 mg/L CI)+DOR Burst (25 mg/L q8h for 24 h),
combination of PMB traditional (fCss of 2 mg/L continuous infusion) and
DOR ‘burst’ (fCmax of 25 mg/L every 8 h×3 doses followed by no DOR
thereafter); PMB (2 mg/L CI)+DOR (25 mg/L q8h), combination of PMB
traditional (fCss of 2 mg/L continuous infusion) and DOR (fCmax of 25 mg/L
every 8 h); PMB Burst (2 mg/L CI on day 1)+DOR (25 mg/L q8h),
combination of PMB ‘burst’ (fCss of 5 mg/L continuous infusion for 24 h
followed by no PMB thereafter) and DOR (fCmax of 25 mg/L every 8 h); PMB
Burst (5 mg/L CI on day 1)+DOR (25 mg/L q8h), combination of PMB
‘burst’ (fCss of 2 mg/L continuous infusion for 24 h followed by no PMB
thereafter) and DOR (fCmax of 25 mg/L every 8 h); PMB Front-Loading
(5 mg/L CI on day 1 then 2 mg/L CI thereafter)+DOR (25 mg/L q8h),
combination of PMB ‘front-loading’ (fCss of 5 mg/L continuous infusion for
24 h followed by fCss of 2 mg/L thereafter) and DOR (fCmax of 25 mg/L
every 8 h). This figure appears in colour in the online version of JAC and in
black and white in the print version of JAC.
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(25 mg/L every 8 h for 24 h thereafter no doses)+Polymyxin B (2 mg/L CI), combination of doripenem ‘burst’ (fCmax of 25 mg/L every 8 h×3 doses followed by no doripenem thereafter)
and polymyxin B traditional (fCss of 2 mg/L as a continuous infusion), (e) Polymyxin B Traditional (2 mg/L CI)+Doripenem (25 mg/L every 8 h), combination of polymyxin B traditional (fCss
of 2 mg/L continuous infusion) and doripenem (fCmax of 25 mg/L every 8 h). (f) Polymyxin B ‘Burst 5’ (5 mg/L CI thereafter no doses)+Doripenem (25 mg/L every 8 h), combination of
polymyxin B ‘burst’ (fCss of 5 mg/L continuous infusion for 24 h followed by no polymyxin B thereafter) and doripenem (fCmax of 25 mg/L every 8 h). (g) Polymyxin B ‘Burst 2’ (2 mg/L CI
thereafter no doses)+Doripenem (25 mg/L every 8 h), combination of polymyxin B ‘burst’ (fCss of 2 mg/L continuous infusion for 24 h followed by no polymyxin B thereafter) and
doripenem (fCmax of 25 mg/L every 8 h). (h) Polymyxin B ‘Front-loading’ (5 mg/L CI for 24 h followed by 2 mg/L CI)+Doripenem (25 mg/L every 8 h), combination of polymyxin B
‘front-loading’ (fCss of 5 mg/L continuous infusion for 24 h followed by fCss of 2 mg/L thereafter) and doripenem (fCmax of 25 mg/L every 8 h). This figure appears in colour in the
online version of JAC and in black and white in the print version of JAC.
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in initial killing up to 3 log10 in the first 6 h, followed by substantial
regrowth (Figure 3). Polymyxin B traditional monotherapy regimens
with fCss of 2 and 5 mg/L showed similar activity against the total
population beyond 8 h and with respect to the emergence of poly-
myxin resistance (Figure 5a and b). Doripenem traditional mono-
therapy (Figure 3) demonstrated bacteriostatic activity over the
entire duration of the experiment and did not alter the emergence
of resistance to polymyxin B (Figure 5c).
The combination of the polymyxin B traditional regimen (fCss of
2 mg/L continuous infusion) and doripenem (fCmax of 25 mg/L
every 8 h) was synergistic against A. baumannii ATCC 19606,
with a 7.5 log10 cfu/mL reduction by 48 h. This combination regi-
men resulted in complete eradication at 72 h that was sustained
until 192 h (Figure 3) and .3 log10 cfu/mL regrowth at 240 h
(Figure 4). The cumulative reduction over time in the log ratio
area of bacterial counts is presented for each regimen in
Table S2. The combination of polymyxin B traditional regimen
and doripenem reduced the time-averaged bacterial load at
each timepoint, with a maximal reduction in AUCcfu of 3.36 log10
by 240 h compared with the growth control (Table S2).
Population analysis profiles confirmed the emergence of resistance,
with polymyxin-resistant subpopulations growing on agar contain-
ing 0–2 mg/L polymyxin B up to 24 h and suppression until 192 h
(Figure 4).
The proposed novel dosing strategies of the combination of
polymyxin B ‘front-loaded’ and doripenem and the combination
of polymyxin B ‘burst’ and doripenem were also evaluated against
a dense bacterial inoculum (109 cfu/mL) of A. baumannii ATCC
19606 in the HFIM (Figure 3). The polymyxin B ‘front-loaded’ com-
bination resulted inmore rapid and extensive initial killing (.8 log10
cfu/mL) with an improved time to eradication. Front-loaded com-
bination regimens completely eradicated A. baumannii at 48 h
compared with traditional combination regimens that resulted in
eradication at 72 h. Additionally, therewas amodest improvement
in bacterial killing with the polymyxin B front-loaded regimen, with
AUCcfu reduction of 3.48 log10 by 240 h compared with the growth
control. Population analysis profiles for the polymyxin B
‘front-loaded’ combination regimen (Figure 5h) resulted in sus-
tained suppression of resistance beyond 48 h until 192 h, withmin-
imal polymyxin B resistance compared with the polymyxin B
traditional combination regimen (Figure 5e).
The combination of doripenem ‘burst’ (fCmax of 25 mg/L every
8 h×3 doses followed by no doripenem thereafter) and poly-
myxin B traditional (fCss of 2 mg/L continuous infusion) did not
affect the total bacterial population beyond 48 h, given the dra-
matic regrowth after the initial 3 log reduction in cfu/mL
between 24 and 48 h (Figure 3). The combination of polymyxin
B ‘burst 5’ (fCss of 5 mg/L continuous infusion for 24 h followed
by no polymyxin B thereafter) and doripenem (fCmax of 25 mg/L
every 8 h) provided rapid initial and sustained killing similar to
the combination of polymyxin B ‘front-loaded’ and doripenem
regimen. There was a 3.49 log10 reduction in AUCcfu compared
with the growth control by 240 h, and cumulative exposure to
polymyxin B over 240 h was reduced to only 25% of the exposure
resulting from the combination of polymyxin B traditional with
doripenem (Table S2). The polymyxin B ‘burst 2’ combination regi-
men, i.e. combination of polymyxin B ‘burst 2’ (fCss of 2 mg/L con-
tinuous infusion for 24 h followed by no polymyxin B thereafter)
and doripenem (fCmax of 25 mg/L every 8 h) resulted in .8 log10
cfu/mL reduction by 72 h with 6 log10 regrowth beyond 144 h,
with an AUCcfu of 2.74 log10 compared with the growth control.
The cumulative exposure to polymyxin B was only 10% of the
combination of polymyxin B traditional with doripenem regimen
(Table S2).
All polymyxin B combination regimens (‘burst’, ‘front-loaded’
and traditional) maintained extremely low bacterial counts near
quantifiable limits over 192 h of the 240 h of therapy, even in the
complete absence of an immune system. The traditional
(Figure 5e), ‘burst 5’ (Figure 5f) and ‘front-loaded’ (Figure 5h) com-
bination regimens demonstrated complete suppression of resistant
subpopulations. Further, the ‘burst 5’ polymyxin combination regi-
men as a 5 mg/L continuous infusion for the first 24 h (Figure 3)
was able to achieve similar early antibacterial killing activity as
the front-loaded regimen and traditional regimens (Figure 3) with
a comparable drug exposure profile. In other words, with only 25%
of the cumulative drug exposure, the polymyxin B ‘burst 5’ combin-
ation demonstrated antibacterial killing activity similar to trad-
itional and ‘front-loaded’ combination strategies.
Discussion
A. baumannii continues to be a pathogen of great medical signifi-
cance.30 To combat this difficult-to-treat pathogen, we deter-
mined that novel dosing strategies centred on polymyxin B
combinations involving ‘front-loading’ and ‘burst’ dosing were
highly promising by maximizing initial killing and suppression of
resistancewhile minimizing cumulative drug exposure and poten-
tial toxicity. Although the front-loaded regimen demonstrated
increased killing, this is balanced against toxicodynamic consid-
erations as the probability of nephrotoxicity increases with
increases in cumulative exposure (AUC). Our data suggest that
front-loaded regimens achieve an exposure of 552 mg.h/L with
similar or greater efficacy over 10 days compared with traditional
dosing regimens with an exposure of 480 mg.h/L. The ‘burst 5’
regimen showed very promising efficacy with exposure of
120 mg.h/L over 10 days. Further reduction of over 50% in poly-
myxin B exposure was achieved by the ‘burst 2’ regimen with an
exposure of 48 mg.h/L over 10 days. Importantly, the ‘burst 5’ and
‘burst 2’ polymyxin regimens were able to achieve nearly identical
antibacterial activity to traditional and ‘front-loaded’ polymyxin
regimens at 25% and 10% of the cumulative polymyxin exposure,
respectively. Polymyxin showed rapid bactericidal activity in vitro
and the PD of polymyxin B is most closely linked to the AUC/MIC
ratio.18 Based on our and previous time–kill studies, monotherapy
with polymyxin B leads to rapid initial decline followed by exten-
sive regrowth. Hence, the combination regimens with administra-
tion of polymyxin in a high-intensity fashion, based on the
mechanism-based modelling, provided an effective way of
addressing the subpopulations that are resistant to either poly-
myxin B or doripenem.
In regards to the mechanistic advantages of polymyxin
combinations, we further refined a previously developed
mechanism-based mathematical model for colistin monother-
apy31 and colistin combinations32 based on the known mechan-
ism of the antibacterial activity of polymyxins and doripenem. The
proposed population PD model well characterized the time-
course of bacterial growth and killing due to monotherapy and
combination regimens against both A. baumannii isolates. This
mathematical model described the rapid concentration-based
killing of polymyxin B monotherapy well. As polymyxin B is
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structurally similar to colistin with the exception of one amino acid
residue, the D-leucine at position 6,33 we based the combination
mathematical model on the known mechanisms of action on
the previously constructed colistin and doripenem mathematical
models and applied them to polymyxin B. We similarly hypothe-
sized that disruption of the bacterial outer membrane by binding
to the lipid A of LPS resulted in increased permeability of the outer
membrane that enhanced the penetration of doripenem and
binding to its target site in the periplasmic membrane.34
Indeed, the model well characterized the dynamics of bacterial
response to polymyxin B combinations. The refinement of this
mathematical model that was now applied to polymyxin B may
serve as an important framework for the design of future
polymyxin-based combination regimens.
By administering polymyxin B in a non-traditional fashion,
these new regimens are promising as they decrease the over-
all exposure while preserving high antibacterial activity. Sandri
and colleagues in their PK study in 24 critically ill patients ex-
plored the lower limit of the current polymyxin B published
dosing guideline of 1.5 mg/kg/day, resulting in an exposure of
228 mg.h/L over 10 days (IQR¼189–292 mg.h/L); at the upper
limit of 2.5 mg/kg/day the exposure is 380 mg.h/L over 10 days
(IQR¼316–487 mg.h/L).24 Pogue et al.14 evaluated the impact
of a colistin loading dose of 5 mg/kg/day on the occurrence of
acute kidney injury and concluded that this colistin loading dose
in 64 patients out of 162 patients was not associated with an
increased risk of acute kidney injury. Therefore, the early, aggres-
sive polymyxin dosing strategies presented here may be of poten-
tial benefit for infections in critically ill patients,manyofwhomare
already at significant risk of developing acute renal injury.
We acknowledge potential limitations in the present study.
Only two A. baumannii isolates were studied: future investigations
should encompass additional strains with differing MIC profiles to
confirm these findings. In profiling the detailed bacterial dynam-
ics over 10 days in HFIMs, it is important to appreciate that these
results were generated in a broth nutrient-rich environment that
was optimal for A. baumannii growth. Although themathematical
model was based on the known mechanisms of action of each
drug, we did not identify killing of quiescent versus non-quiescent
cells or quantify the relative contributions of each antibiotic to
bacterial killing. The PD response of combinations presented in
this investigation may also differ in biological fluids, particularly
considering the differences in site-specific PK in humans. It is
also important to note that interaction of polymyxin B together
with doripenem may also differ in patients, as it has been
shown that there is a unique relationship between granulocyte-
mediated killing and antibiotics.35 Finally, there have been no con-
trolled human studies evaluating these new high-intensity dosing
regimens of polymyxin B. Overall, these new findings are promis-
ing and systemic evaluation of novel polymyxin combination dos-
ing strategies in vivo is necessary for future translation to the
clinical setting.
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